Precision Navigation to Improve Community Cancer Screening Participation
Effectiveness and Mechanisms of a Precision Navigation Intervention to Improve Community Cancer Screening Participation: A Dual-Cohort Cluster Randomized Controlled Trial
This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China.
Eligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment.
This is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers.
Participants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment.
The main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention.
The results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Haifan Xiao
- Número de teléfono: 8615580869827
- Correo electrónico: xiaohaifan@hnca.org.cn
Ubicaciones de estudio
-
-
Hunan
-
Huaihua, Hunan, Porcelana
- Reclutamiento
- Huaihua Central Hospital (Huaihua Cancer Hospital)
-
Contacto:
- Qiang Yan
- Número de teléfono: 8615111549588
- Correo electrónico: 383114173@qq.com
-
Shaoyang, Hunan, Porcelana
- Reclutamiento
- Shaoyang Hospital of Traditional Chinese Medicine
-
Contacto:
- Liping Deng
- Número de teléfono: 8618473926876
-
Yongzhou, Hunan, Porcelana
- Reclutamiento
- Yongzhou Central Hospital
-
Contacto:
- Suzhen He
- Número de teléfono: 8613974618396
- Correo electrónico: 25187557@qq.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Aged 45 to 74 years.
- Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months.
- Participating in the urban cancer screening program.
- Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.
- Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types.
- Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.
- Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires.
- Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months.
- Currently participating in another interventional study that may affect cancer screening behavior.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Poner en pantalla
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Usual Health Education Group
Participants in communities assigned to this group will receive general cancer screening health education materials, including information about cancer prevention, early detection, and recommended screening tests.
|
Participants in the usual health education group will receive general cancer screening education materials.
The materials will provide basic information about cancer prevention, early detection, and screening for lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, and liver cancer.
The content is not personalized according to the participant's individual risk profile.
|
|
Sin intervención: Waiting Control Group
Participants in communities assigned to this group will not receive active screening promotion during the main intervention period.
They will continue to have access to the free cancer screening services provided by the urban cancer screening program.
General health education materials will be provided after the primary assessment.
|
|
|
Experimental: Precision Navigation Group
Participants in communities assigned to this group will receive a personalized electronic precision navigation report based on their cancer risk profile.
The report will explain the recommended screening tests, support screening decision-making, and provide practical steps to facilitate screening completion.
|
Participants in the precision navigation group will receive a personalized navigation report based on their cancer risk profile from the urban cancer screening program.
The report will be tailored according to whether the participant is at high risk for three or more cancers or for one or two cancers.
It will provide individualized information on high-risk cancer types, recommended screening tests, screening procedures, common barriers to screening, and practical action steps.
Trained staff will provide a brief standardized explanation of the report and support participants in making a screening action plan.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants Completing Recommended Cancer Screening
Periodo de tiempo: From enrollment to 6 months after enrollment
|
The proportion of enrolled high-risk participants who complete at least one recommended clinical screening test for their corresponding high-risk cancer type or types during follow-up.
Screening completion will be determined using records from the urban cancer screening program information system and participating screening institutions.
|
From enrollment to 6 months after enrollment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Participants Completing All Recommended Cancer Screening Tests
Periodo de tiempo: From enrollment to 3 months after enrollment
|
This outcome is defined as the proportion of participants who complete all cancer screening tests recommended for their individual high-risk cancer profile during follow-up.
Screening completion will be determined using records from the urban cancer screening program information system and participating screening institutions.
|
From enrollment to 3 months after enrollment
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades intestinales
- Enfermedades de las vías respiratorias
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades pulmonares
- Enfermedades del HIGADO
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades del Colon
- Enfermedades de la piel
- Enfermedades de los senos
- Enfermedades de la piel y del tejido conectivo
- Neoplasias Pulmonares
- Neoplasias colorrectales
- Neoplasias de mama
- Neoplasias Gastrointestinales
- Neoplasias Hepaticas
Otros números de identificación del estudio
- KY2026044
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .